Press release
Vasomotor Symptoms Market to Grow at a Substantial Growth Rate During the Forecast Period | TherapeuticsMD, Mithra Pharmaceuticals (Donesta Biosciences), KaNDy Therapeutics, Fervent Pharmaceuticals
Vasomotor Symptoms Market
DelveInsight's " [https://www.delveinsight.com/report-store/vasomotor-symptoms-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Vasomotor Symptoms market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Vasomotor Symptoms market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vasomotor Symptoms (Hot flashes/Night sweats) Overview
Vasomotor Symptoms (VMS) manifest as episodes of intense heat accompanied by sweating and flushing, primarily affecting areas like the head, neck, chest, and upper back. These symptoms, often coupled with hot flashes and night sweats, are widely regarded as hallmark signs of menopause. Additionally, VMS may entail heart palpitations and fluctuations in blood pressure.
These symptoms arise due to fluctuations in gonadal hormones, disrupting the body's temperature regulation mechanisms. Core body temperature (CBT) typically maintains within a specific range, influenced by daily circadian rhythms. Processes involved in heat conservation and dissipation play crucial roles in sustaining optimal internal organ function, necessitating precise regulation of CBT.
The North American Menopause Society (NAMS) advises against treatment until VMS significantly impact a woman's well-being. The decision to initiate treatment hinges on symptom severity, evaluation of treatment-associated risks, and the individual's perspectives on menopause and medication. For most women, VMS diminish over time without requiring intervention.
Vasomotor Symptoms (Hot flashes/Night sweats) Market Key Facts
*
In the year 2021, the total prevalent cases of Vasomotor Symptoms were ~136 Million cases in the 7MM, which might decrease by 2032 at a mild CAGR. In the 7MM, the highest number of prevalent cases of Vasomotor Symptoms were observed in the US.
*
In EU4 and the UK, the prevalent cases of Vasomotor Symptoms were ~60 Million cases in the year 2021, which is estimated to decrease by the year 2032 at a mild CAGR. In the EU4 and the UK, the highest number of prevalent cases of Vasomotor Symptoms was observed in Germany.
*
As per the DelveInsight estimates, the total treated cases of Vasomotor Symptoms were highest in the US, followed by Japan, the UK, etc.
*
According to the DelveInsight estimates, the total number of treated cases of Vasomotor Symptoms was 7.47 million cases, respectively, in the 7MM, in the year 2021.
*
According to DelveInsight's analysis, VMS is most prevalent in females at age 60-65 years old.
[https://www.delveinsight.com/report-store/vasomotor-symptoms-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Vasomotor Symptoms market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Vasomotor Symptoms market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vasomotor Symptoms (Hot flashes/Night sweats) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology, Segmented by -
*
Total Prevalent Cases of Vasomotor Symptoms (VMS) in the 7MM (2019-2032)
*
Total Treated Cases of Vasomotor Symptoms (VMS) in the 7MM (2019-2032)
*
Total Severity-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019-2032)
*
Total Age-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019-2032)
Vasomotor Symptoms (Hot flashes/Night sweats) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to be launched during the study period. The analysis covers the Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vasomotor Symptoms pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vasomotor Symptoms Market Will Evolve and Grow by 2032 @ [https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Vasomotor Symptoms (Hot flashes/Night sweats) Therapeutics Analysis
The Leading Companies in the Vasomotor symptoms (Hot flashes/Night sweats) Therapeutics Market Include:
*
TherapeuticsMD
*
Mithra Pharmaceuticals (Donesta Biosciences)
*
KaNDy Therapeutics
*
Fervent Pharmaceuticals
*
Astellas Pharma
*
Sojournix
*
Mitsubishi Tanabe Pharma
*
Bayer
*
Nerre Therapeutics Ltd
*
Astellas Pharma
*
MenoGeniX
*
Mitsubishi Tanabe Pharma
*
QUE Oncology
And Many Others
Vasomotor symptoms (Hot flashes/Night sweats) Therapies [https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Covered in the Report Include:
*
Donesta (E4, Estetrol): Estetra/ Mithra Pharmaceuticals
*
Elinzanetant (BAY-3427080, NT 814): Bayer/Nerre Therapeutics Ltd.
*
Fezolinetant (ESN-364): Astellas Pharma
*
MNGX-100(Filgrastim, G-CSF): MenoGeniX
*
Elismetrep (MT-8554): Mitsubishi Tanabe Pharma
*
Q-122 (MSX-122): QUE Oncology
*
MT-8554: Mitsubishi Tanabe Pharma
*
FP-101: Fervent Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ [https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Key Insights
2. Executive Summary
3. Vasomotor Symptoms Competitive Intelligence Analysis
4. Vasomotor Symptoms Market Overview at a Glance
5. Vasomotor Symptoms Disease Background and Overview
6. Vasomotor Symptoms Patient Journey
7. Vasomotor Symptoms Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices
9. Vasomotor Symptoms Unmet Needs
10. Key Endpoints of Vasomotor Symptoms Treatment
11. Vasomotor Symptoms Marketed Products
12. Vasomotor Symptoms Emerging Drugs and Latest Therapeutic Advances
13. Vasomotor Symptoms Seven Major Market Analysis
14. Attribute Analysis
15. Vasomotor Symptoms Market Outlook (In US, EU5, and Japan)
16. Vasomotor Symptoms Access and Reimbursement Overview
17. KOL Views on the Vasomotor Symptoms Market
18. Vasomotor Symptoms Market Drivers
19. Vasomotor Symptoms Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vasomotor-symptoms-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-therapeuticsmd-mithra-pharmaceuticals-donesta-biosciences-kandy-therapeutics-fervent-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vasomotor Symptoms Market to Grow at a Substantial Growth Rate During the Forecast Period | TherapeuticsMD, Mithra Pharmaceuticals (Donesta Biosciences), KaNDy Therapeutics, Fervent Pharmaceuticals here
News-ID: 3487943 • Views: …
More Releases from ABNewswire
Vocodia Is Ushering In A New Era And Setting A High Benchmark For Conversational …
Vocodia Holdings (CBOE: VHAI) is doing things many companies can't- providing clients with conversational AI technology that is, in many ways, a game-changing product for the service sector. That can translate to being more than good news for Vocodia from a growth perspective; it can be for investors as well, especially with CBOE-listed Vocodia making strides to tap into a global conversational AI market opportunity that Brainy Insights estimated to…
SuperCom Stock Earns Bullish Nod As Investors Show Interest In Its Real-Time Mon …
SuperCom (NASDAQ: SPCB) stock is bucking the bearish trend, trading 17% higher since April despite a challenging market backdrop. While indeed impressive, the better news for SuperCom and its investors is that the bullish bias sending shares higher is likely to continue. Why? Because this microcap company keeps signing deals.
Last month, SuperCom announced receiving over $5 million of new orders from European government clients. Better still, the revenues from that…
U.S. Gold Corp Scores Permitting Milestone At CK Gold Project, Shares Set New 52 …
Shares in U.S. Gold Corp (NASDAQ: USAU [https://www.usgoldcorp.gold/]) are in rally mode, trading at $5.37 on Wednesday at the time of this writing, which is over 46% higher than when they started Q2. The potentially better news for investors is that the rally is news-supported and, more importantly, sets the foundation for the steepening share price trajectory to continue.
Those following U.S. Gold Corp already know why, including recognizing value potential…
Treatment.com AI Inc (CSE: TRUE) Partners with Novus Health to Support Over 1.5 …
Dr. Essam Hamza, CEO of Treatment, comments: "We are very excited to partner with a recognized leading healthcare firm in Novus Health. There is a near term opportunity to implement our proprietary AI diagnostic tools into the solutions offered to their vast customer base. However, with this collaboration we also have an opportunity to extend into new mutually developed tools and solutions that have the ability to further improve health…
More Releases for Vasomotor
Vasomotor Symptoms of Menopause Market to be at Forefront by 2024
Menopause is the stage during which women stop producing ovaries and there is an end of the fertile phase. It occurs in 85% of premenopausal women during their late 40s, resulting in the cessation of their menstrual cycle. Due to the cessation of menstrual flow, the production of estrogen decreases and gonadotropin increases, which gives rise to various physiological and psychological changes, called vasomotor symptoms. Vasomotor symptoms of menopause are…
Vasomotor Symptoms of Menopause Treatment Market Investment Research Report 2016 …
Eggs production process gets halted during the menopause condition, as the body produces less progesterone and estrogen the menstrual cycle slows down and eventually stops this results to various erratic symptoms. Most of the times these symptoms are manageable without clinical treatment but in many cases some form of treatment is required. According to the WHO statistics of 2015, the global sex ration is nearly 101.7, it is an indication…
Vasomotor Symptoms of Menopause Treatment Market Trends & Projection to 2024
Vasomotor symptoms of menopause treatment market is expected to grow at healthy growth rate in forecast period due to rise aging population, incidences of vasomotor symptoms of menopause will mostly increase in the near future will boost the market growth. Moreover increasing awareness about medication to treat vasomotor symptoms. Many companies are currently conducting clinical trials to develop drug molecules specific for vasomotor symptoms of menopause.
Request for Table of Contents…
Latest Trend Of Vasomotor Symptoms of Menopause - Pipeline Review, H2 2017
"The Report Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.
Vasomotor symptoms of menopause include hot…
Vasomotor Symptoms of Menopause Treatment Market to Develop by 2024
Eggs production process gets halted during the menopause condition, as the body produces less progesterone and estrogen the menstrual cycle slows down and eventually stops this results to various erratic symptoms. Most of the times these symptoms are manageable without clinical treatment but in many cases some form of treatment is required. According to the WHO statistics of 2015, the global sex ration is nearly 101.7, it is an indication…
Vasomotor Symptoms of Menopause Market Share by Industry Research 2016 - 2024
Global Vasomotor Symptoms of Menopause Market: Overview
Menopause is the stage during which women stop producing ovaries and there is an end of the fertile phase. It occurs in 85% of premenopausal women during their late 40s, resulting in the cessation of their menstrual cycle. Due to the cessation of menstrual flow, the production of estrogen decreases and gonadotropin increases, which gives rise to various physiological and psychological changes, called vasomotor…
